Population pharmacokinetics of teicoplanin and dosage optimization in sepsis patients based on continuous renal replacement therapy

PurposeIt is well known that pharmacokinetics (PK) of drugs is significantly altered in sepsis patients receiving continuous renal replacement therapy (CRRT). However, clinical studies investigating the PK of drugs administered during CRRT are limited, and appropriate dosing regimens have not yet to...

Full description

Saved in:
Bibliographic Details
Main Authors: Qian Sun, Jiang Jian, Xueqiang Zhou, Zhu Hong, Suwen Yang, Yanping Zheng, Siyi Wang, Maojun Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1621959/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849424782451277824
author Qian Sun
Jiang Jian
Xueqiang Zhou
Zhu Hong
Suwen Yang
Yanping Zheng
Siyi Wang
Maojun Zhao
author_facet Qian Sun
Jiang Jian
Xueqiang Zhou
Zhu Hong
Suwen Yang
Yanping Zheng
Siyi Wang
Maojun Zhao
author_sort Qian Sun
collection DOAJ
description PurposeIt is well known that pharmacokinetics (PK) of drugs is significantly altered in sepsis patients receiving continuous renal replacement therapy (CRRT). However, clinical studies investigating the PK of drugs administered during CRRT are limited, and appropriate dosing regimens have not yet to be definitively established. The study aimed to develop a population PK model for teicoplanin, explore significant covariates regarding to teicoplanin PK, and propose optimal dosage strategies for sepsis patients.MethodsEighty-six sepsis patients were included and plasma samples from all patients were analyzed. PK analysis was conducted on samples from 86 sepsis patients, followed by population PK analysis and simulations to ascertain the probability of target attainment (PTA).ResultsTeicoplanin was well characterized by a one-compartment PK model with first-order elimination. The presence of CRRT was associated with a lower volume of distribution (V), and gender was associated with a higher V. When MIC was set at 1 mg/L, a loading dose of 800 mg (q12h) followed by a maintenance dose of 600 mg (q24h) was necessary for male sepsis patients without CRRT, and a loading dose of 800 mg (q12h) followed by a maintenance dose of 800 mg (q24h) for male sepsis patients receiving CRRT. Female patients with sepsis required a loading dose of 1,000 mg q12h followed by a maintenance dose of 1,000 mg q24h.ConclusionTeicoplanin therapy in sepsis patients undergoing CRRT necessitates individualized dosing. A PK model-based teicoplanin dosing regimen for sepsis patients with CRRT was proposed, whereas prospective clinical study is required to validate.
format Article
id doaj-art-49b3d2518e564eeeb45701525e9b558d
institution Kabale University
issn 1663-9812
language English
publishDate 2025-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-49b3d2518e564eeeb45701525e9b558d2025-08-20T03:30:01ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-07-011610.3389/fphar.2025.16219591621959Population pharmacokinetics of teicoplanin and dosage optimization in sepsis patients based on continuous renal replacement therapyQian Sun0Jiang Jian1Xueqiang Zhou2Zhu Hong3Suwen Yang4Yanping Zheng5Siyi Wang6Maojun Zhao7Department of Intensive Care Unit, Beijing Jishuitan Hospital Guizhou Hospital, Guiyang, Guizhou, ChinaDepartment of Intensive Care Unit, Beijing Jishuitan Hospital Guizhou Hospital, Guiyang, Guizhou, ChinaDepartment of Intensive Care Unit, Beijing Jishuitan Hospital Guizhou Hospital, Guiyang, Guizhou, ChinaDepartment of Pathogenic microorganism, Bijie Medical College, Bijie, Guizhou, ChinaDepartment of Clinical Laboratory Medicine, Kaiyang County People’s Hospital, Guiyang, Guizhou, ChinaDepartment of Intensive Care Unit, Beijing Jishuitan Hospital Guizhou Hospital, Guiyang, Guizhou, ChinaDepartment of Pharmacy, Huadu District People’s Hospital of Guangzhou, Guangzhou, ChinaDepartment of Intensive Care Unit, Beijing Jishuitan Hospital Guizhou Hospital, Guiyang, Guizhou, ChinaPurposeIt is well known that pharmacokinetics (PK) of drugs is significantly altered in sepsis patients receiving continuous renal replacement therapy (CRRT). However, clinical studies investigating the PK of drugs administered during CRRT are limited, and appropriate dosing regimens have not yet to be definitively established. The study aimed to develop a population PK model for teicoplanin, explore significant covariates regarding to teicoplanin PK, and propose optimal dosage strategies for sepsis patients.MethodsEighty-six sepsis patients were included and plasma samples from all patients were analyzed. PK analysis was conducted on samples from 86 sepsis patients, followed by population PK analysis and simulations to ascertain the probability of target attainment (PTA).ResultsTeicoplanin was well characterized by a one-compartment PK model with first-order elimination. The presence of CRRT was associated with a lower volume of distribution (V), and gender was associated with a higher V. When MIC was set at 1 mg/L, a loading dose of 800 mg (q12h) followed by a maintenance dose of 600 mg (q24h) was necessary for male sepsis patients without CRRT, and a loading dose of 800 mg (q12h) followed by a maintenance dose of 800 mg (q24h) for male sepsis patients receiving CRRT. Female patients with sepsis required a loading dose of 1,000 mg q12h followed by a maintenance dose of 1,000 mg q24h.ConclusionTeicoplanin therapy in sepsis patients undergoing CRRT necessitates individualized dosing. A PK model-based teicoplanin dosing regimen for sepsis patients with CRRT was proposed, whereas prospective clinical study is required to validate.https://www.frontiersin.org/articles/10.3389/fphar.2025.1621959/fullteicoplaninpharmacokineticsdosage optimizationsepsiscontinuous renal replacement therapy
spellingShingle Qian Sun
Jiang Jian
Xueqiang Zhou
Zhu Hong
Suwen Yang
Yanping Zheng
Siyi Wang
Maojun Zhao
Population pharmacokinetics of teicoplanin and dosage optimization in sepsis patients based on continuous renal replacement therapy
Frontiers in Pharmacology
teicoplanin
pharmacokinetics
dosage optimization
sepsis
continuous renal replacement therapy
title Population pharmacokinetics of teicoplanin and dosage optimization in sepsis patients based on continuous renal replacement therapy
title_full Population pharmacokinetics of teicoplanin and dosage optimization in sepsis patients based on continuous renal replacement therapy
title_fullStr Population pharmacokinetics of teicoplanin and dosage optimization in sepsis patients based on continuous renal replacement therapy
title_full_unstemmed Population pharmacokinetics of teicoplanin and dosage optimization in sepsis patients based on continuous renal replacement therapy
title_short Population pharmacokinetics of teicoplanin and dosage optimization in sepsis patients based on continuous renal replacement therapy
title_sort population pharmacokinetics of teicoplanin and dosage optimization in sepsis patients based on continuous renal replacement therapy
topic teicoplanin
pharmacokinetics
dosage optimization
sepsis
continuous renal replacement therapy
url https://www.frontiersin.org/articles/10.3389/fphar.2025.1621959/full
work_keys_str_mv AT qiansun populationpharmacokineticsofteicoplaninanddosageoptimizationinsepsispatientsbasedoncontinuousrenalreplacementtherapy
AT jiangjian populationpharmacokineticsofteicoplaninanddosageoptimizationinsepsispatientsbasedoncontinuousrenalreplacementtherapy
AT xueqiangzhou populationpharmacokineticsofteicoplaninanddosageoptimizationinsepsispatientsbasedoncontinuousrenalreplacementtherapy
AT zhuhong populationpharmacokineticsofteicoplaninanddosageoptimizationinsepsispatientsbasedoncontinuousrenalreplacementtherapy
AT suwenyang populationpharmacokineticsofteicoplaninanddosageoptimizationinsepsispatientsbasedoncontinuousrenalreplacementtherapy
AT yanpingzheng populationpharmacokineticsofteicoplaninanddosageoptimizationinsepsispatientsbasedoncontinuousrenalreplacementtherapy
AT siyiwang populationpharmacokineticsofteicoplaninanddosageoptimizationinsepsispatientsbasedoncontinuousrenalreplacementtherapy
AT maojunzhao populationpharmacokineticsofteicoplaninanddosageoptimizationinsepsispatientsbasedoncontinuousrenalreplacementtherapy